A Multicentre, Randomised, Double-blind, Parallel Group, Placebo-controlled, Time-to-first Asthma Exacerbation Phase III Efficacy and Safety Study of Benralizumab in Paediatric Patients With Severe Eosinophilic Asthma
Clinical trial NCT05692180 · ACTIVE_NOT_RECRUITING
Trial details
- NCT number
- NCT05692180
- Sponsor
- AstraZeneca
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- Phase 3
- Study type
- INTERVENTIONAL
- Start date
- 2023-04-05
- Primary completion
- 2030-05-05
- Enrollment
- 94
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.